Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Mark Millich, 26 years old and insecure about his thinning hair, was curious about the ads he saw promising to reverse his ...

Hims and Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...

Hims Hard Mints are a discreet alternative to erectile dysfunction pills. They’re created by a ... and daily generic Cialis yes 4.0 out of 5 Hims • starts at $958 for 1-month supply of daily ...

BofA analyst Allen Lutz notes that the Food and Drug Administration yesterday provided updated enforcement timelines for semaglutide and ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...

Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair loss can ...

Hims & Hers (HIMS) stock plunged 27% on Tuesday ... The company forecast full-year revenue of $2.3 billion to $2.4 billion, higher than the consensus Wall Street estimate of $2.09 billion.

Hims & Hers is set to continue offering weight-loss pills and personalized weight-loss support, including nutrition plans and coaching. Outside of weight-loss care, the company saw its subscriber ...